The European Medicines Agency review of the initial application of atezolizumab and the role of PD-L1 expression as biomarker for checkpoint inhibitors

por Araujo-Fernandez, I., Delgado, J., Moscetti, L., Sarac, S.B., Zander, H., Mueller-Egert, S., Dunder, K., Pean, E., Bergmann, L., Enzmann, H., Pignatti, F.
Publicado 2020